PMID- 19272639
OWN - NLM
STAT- MEDLINE
DCOM- 20090518
LR  - 20211020
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Print)
IS  - 0090-8258 (Linking)
VI  - 113
IP  - 3
DP  - 2009 Jun
TI  - Associations between ERBB2 amplification and progression-free survival and 
      overall survival in advanced stage, suboptimally-resected epithelial ovarian 
      cancers: a Gynecologic Oncology Group Study.
PG  - 341-7
LID - 10.1016/j.ygyno.2009.02.009 [doi]
AB  - OBJECTIVE(S): The Gynecologic Oncology Group (GOG) examined the association 
      between ERBB2 amplification and clinical covariates, tumor response, disease 
      status post-chemotherapy, progression-free survival (PFS), and overall survival 
      (OS) in epithelial ovarian cancer (EOC). METHODS: Women with 
      suboptimally-resected, advanced stage EOC who participated in GOG-111, a 
      multi-center randomized phase III trial of cyclophosphamide+cisplatin versus 
      paclitaxel+cisplatin, and provided a tumor block through the companion protocol 
      GOG-9404 were eligible. ERBB2 amplification was examined using fluorescence in 
      situ hybridization (FISH) with probes for ERBB2 and the centromere of chromosome 
      17 (CEP17). RESULTS: ERBB2 amplification, defined as >2 copies of ERBB2/CEP17, 
      was a rare event in EOC with 7% (9/133) of women exhibiting between 2.2 and 33.7 
      copies of ERBB2/CEP17, and was not associated with patient age, race, GOG 
      performance status, stage, cell type, grade, measurable disease status, volume of 
      ascites, tumor response or disease status post-chemotherapy. Women with >2 verses 
      < or =2 copies of ERBB2/CEP17 did not have a reduced risk of disease progression 
      (hazard ratio [HR]=0.56; 95% confidence interval [CI]=0.27-1.16; p=0.120) or 
      death (HR=0.57; 95% CI=0.26-1.23; p=0.152), and ERBB2 amplification was not an 
      independent prognostic factor for PFS or OS. ERBB2 amplification, defined as >4 
      copies of ERBB2/nuclei, was observed in 9% (12/133) of women with levels ranging 
      from 4.2 to 49.2 copies of ERBB2/nuclei, and was associated with older age and 
      volume of ascites, but not with the other clinical covariates or outcome. 
      CONCLUSION(S): ERBB2 amplification is a rare event and has no predictive or 
      prognostic value in suboptimally-resected, advanced stage EOC treated with 
      platinum-based combination chemotherapy.
FAU - Farley, John
AU  - Farley J
AD  - Department of Obstetrics and Gynecology, Uniformed Services University of the 
      Health Sciences, Bethesda, MD 20814, USA.
FAU - Fuchiuji, Sartoru
AU  - Fuchiuji S
FAU - Darcy, Kathleen M
AU  - Darcy KM
FAU - Tian, Chunqiao
AU  - Tian C
FAU - Hoskins, William J
AU  - Hoskins WJ
FAU - McGuire, William P
AU  - McGuire WP
FAU - Hanjani, Parviz
AU  - Hanjani P
FAU - Warshal, David
AU  - Warshal D
FAU - Greer, Benjamin E
AU  - Greer BE
FAU - Belinson, Jerome
AU  - Belinson J
FAU - Birrer, Michael J
AU  - Birrer MJ
LA  - eng
GR  - U10 CA037517/CA/NCI NIH HHS/United States
GR  - Z01 SC000164/ImNIH/Intramural NIH HHS/United States
GR  - CA 37517/CA/NCI NIH HHS/United States
GR  - CA 27469/CA/NCI NIH HHS/United States
GR  - U10 CA027469/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
DEP - 20090309
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Clinical Trials, Phase II as Topic
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - *Gene Amplification
MH  - *Genes, erbB-2
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Ovarian Neoplasms/drug therapy/*genetics
MH  - Prognosis
MH  - Randomized Controlled Trials as Topic
MH  - Young Adult
PMC - PMC6944288
MID - NIHMS1064764
COIS- Conflict of interest statement The authors declare that there are no conflicts of 
      interest with the exception of Dr. William J. Hoskins who reports that he is 
      CoChair NCI Gynecologic Cancer Steering Committee, Member of the Executive Board 
      of ACOG, Investor of Chestnut Medical and his spouse is the Vice President of the 
      ACOG.
EDAT- 2009/03/11 09:00
MHDA- 2009/05/19 09:00
PMCR- 2020/01/06
CRDT- 2009/03/11 09:00
PHST- 2008/12/11 00:00 [received]
PHST- 2009/01/29 00:00 [revised]
PHST- 2009/02/04 00:00 [accepted]
PHST- 2009/03/11 09:00 [entrez]
PHST- 2009/03/11 09:00 [pubmed]
PHST- 2009/05/19 09:00 [medline]
PHST- 2020/01/06 00:00 [pmc-release]
AID - S0090-8258(09)00081-X [pii]
AID - 10.1016/j.ygyno.2009.02.009 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2009 Jun;113(3):341-7. doi: 10.1016/j.ygyno.2009.02.009. Epub 2009 
      Mar 9.